Bio-Path Holdings Navigates Market Volatility Amid Biotech Challenges
Bio-Path Holdings, a biotech company focused on RNAi nanoparticle drug development, faces market volatility and challenges, but its innovative approach to oncology treatment holds long-term potential.
2 minutes to read